AIM	Absent in melanoma
APC	Antigen-presenting cells
ASCO	American Society of Clinical Oncology
cGAS	cGAMP synthase
CDCA1	Cell division cycle associated gene 1
CIN	Cervical intraepithelial neoplasia
COPV	Canine papillomavirus-associated oral cancer
CR	Complete response
CTL	Cytotoxic T lymphocytes
CTLA	Cytotoxic T lymphocyte-associated protein
DCs	Dendritic cells
FDA	Food and Drug Administration
GM-CSF	Granulocyte-macrophage colony-stimulating factor
HLA	Human leukocyte antigen
HPV	Human papillomavirus
ICI	Immune checkpoint inhibitors
IFI	Interferon-γ-inducible protein
IL	Interleukin
IMP3	Insulin-like growth factor-II mRNA-binding protein 3
INF	Interferon
LP	Long peptide
LY6K	Lymphocyte antigen 6 complex locus K (LY6K)
MAGE-A3	Melanoma antigen E-A3
MHC	Major histocompatibility complex
NSCLC	Non-small cell lung cancer
OPC	Oropharyngeal cancers
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PD-(L)	Programmed death–(ligand)
PFS	Progression-free survival
PR	Partial response
RB	Retinoblastoma
R/M	Recurrent/metastatic
SAE	Severe adverse event
HNSCC	Squamous cell carcinoma of the head and neck
SD	Stable disease
SP	Short peptide
TAA	Tumor-associated antigen
TCR	T cell receptor
TIL	Tumor-invasive T lymphocyte
TIM	T cell immunoglobulin- and mucin-domain-containing molecule
TLR	Toll-like receptor
TNF	Tumor necrosis factor
T-reg	Regulatory T cells